Johnson & Johnson: Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios With Multiple Data Presentations at ESMO 2019
September 19, 2019
September 19, 2019
RARITAN, New Jersey, Sept. 19 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- Second interim analysis from the Phase 3 SPARTAN study reporting updated overall survival results in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA (apalutamide)
- Patient-reported outcomes from the Phase 3 TITAN study evaluating ERLEADA(R) in patients with metastatic castr . . .
* * *
- Second interim analysis from the Phase 3 SPARTAN study reporting updated overall survival results in patients with non-metastatic castration-resistant prostate cancer treated with ERLEADA (apalutamide)
- Patient-reported outcomes from the Phase 3 TITAN study evaluating ERLEADA(R) in patients with metastatic castr . . .